{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+nasal&page=2",
    "query": {
      "intervention": "placebo nasal",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 583,
    "total_pages": 59,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+nasal&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+nasal&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T11:47:03.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00609674",
      "title": "A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rhinitis, Allergic, Perennial"
      ],
      "interventions": [
        {
          "name": "Fluticasone furoate nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2008-01",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 12,
      "location_summary": "Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Wheaton",
          "state": "Maryland"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00609674"
    },
    {
      "nct_id": "NCT01680718",
      "title": "Neuropeptides and Social Behavior",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Social Psychology"
      ],
      "interventions": [
        {
          "name": "Intranasal oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Intranasal vasopressin",
          "type": "DRUG"
        },
        {
          "name": "Intranasal placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 160,
      "start_date": "2012-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-28",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01680718"
    },
    {
      "nct_id": "NCT00682643",
      "title": "A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rhinitis, Allergic, Perennial"
      ],
      "interventions": [
        {
          "name": "fluticasone furoate nasal spray",
          "type": "DRUG"
        },
        {
          "name": "vehicle placebo nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2008-06",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 56,
      "location_summary": "Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more",
      "locations": [
        {
          "city": "Oxford",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00682643"
    },
    {
      "nct_id": "NCT00910689",
      "title": "Drug and Non-Drug Treatment Of Severe Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine Headache"
      ],
      "interventions": [
        {
          "name": "Propranolol or nadolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "DRUG"
        },
        {
          "name": "Behavioral Migraine Management (BMM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Optimal Acute Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 232,
      "start_date": "2001-07",
      "completion_date": "2005-11",
      "has_results": true,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 2,
      "location_summary": "Athens, Ohio • Westerville, Ohio",
      "locations": [
        {
          "city": "Athens",
          "state": "Ohio"
        },
        {
          "city": "Westerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910689"
    },
    {
      "nct_id": "NCT04957758",
      "title": "Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurotrophic Keratopathy"
      ],
      "interventions": [
        {
          "name": "OC-01 (varenicline) nasal spray 1.2 mg/ml",
          "type": "DRUG"
        },
        {
          "name": "Placebo (vehicle) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2021-06-17",
      "completion_date": "2023-04-28",
      "has_results": true,
      "last_update_posted_date": "2024-05-07",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 31,
      "location_summary": "Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04957758"
    },
    {
      "nct_id": "NCT06489548",
      "title": "Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia",
        "Alzheimers Disease",
        "Mild Cognitive Impairment Due to Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Foralumab TZLS-401 50 µg",
          "type": "DRUG"
        },
        {
          "name": "Foralumab TZLS-401 100 µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-09-16",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06489548"
    },
    {
      "nct_id": "NCT02890381",
      "title": "Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV LID cp ΔM2-2 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 17,
      "start_date": "2016-10-05",
      "completion_date": "2017-04-24",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890381"
    },
    {
      "nct_id": "NCT02225912",
      "title": "A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Upper Respiratory Infections"
      ],
      "interventions": [
        {
          "name": "PrevinC",
          "type": "OTHER"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "BioHealth Technologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2005-02",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 6,
      "location_summary": "Hialeah, Florida • Miami, Florida • Miami Beach, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02225912"
    },
    {
      "nct_id": "NCT05332067",
      "title": "Omalizumab Before Onset of Exacerbations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Atopy",
        "Viral Upper Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 300,
      "start_date": "2022-05-01",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332067"
    },
    {
      "nct_id": "NCT01592214",
      "title": "Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcal Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "XF-73 in 2% Klucel gel",
          "type": "DRUG"
        },
        {
          "name": "XF-73 in 4% Klucel gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-05",
      "last_synced_at": "2026-10-05T11:47:03.784Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592214"
    }
  ]
}